BrainScope

Coming – November 5

BrainScope Showcases Its Technology On A Global Stage

Date and Time

November 5

–

4:00 PM ET 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

BrainScope is revolutionizing brain health diagnostics by applying AI to brain electrical activity (EEG). Their AI-driven platform provides objective radiation-free assessment of neurological conditions. Their technology is so promising, as one of just 10 Scale Up semi-finalists in the Global Health Exhibition 2025 NextGen Pitch Competition BrainScope recently had the opportunity to showcase their vision for advancing brain health on a global stage.

BrainScope’s AI-driven platform has led to the development of objective, FDA-cleared biomarkers that enable rapid, radiation-free assessment of neurological conditions, offering a powerful alternative to MRIs and CT scans.

Beyond head injury, BrainScope has developed a proof-of-concept biomarker that predicts the earliest onset of Alzheimer’s in individuals with memory complaints, supported by investment from the Alzheimer’s Drug Discovery Foundation. They are in discussions with multiple top-tier brand collaborators to develop a rapid stroke indication. And their biomarkers have the potential to upend CNS drug development, reducing the high costs and failure rates by helping identify the right patients for the right drugs.

Join our online event with BrainScope CEO, Laurie Silver, to hear more about how their technology is also helping improve the diagnosis and treatment of other neurological conditions including stroke, Alzheimer’s, and other clinical trial services, uniquely positioning the company in a $21B+ global market.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.